Abstract
Despite recent advances, cardiovascular disease continues to be the leading cause of death among patients with diabetes. Diabetes-related heart disease makes up the majority of the cardiovascular morbidity and mortality and this clinical entity results from synergistic interaction amongst various overlapping mechanisms. Diabetes-related heart disease is characterised by a propensity to develop premature, diffuse atherosclerotic disease, structural and functional abnormalities of the microvasculature, autonomic dysfunction and intrinsic myocardial dysfunction (the so-called diabetic ‘cardiomyopathy’), all of which are exacerbated by hypertension and diabetic nephropathy. The renin-angiotensinaldosterone system possesses various autocrine and paracrine effects which drive most of the pathophysiological mechanisms in diabetes-related heart disease. This review aims to describe the expanding role of the renin-angiotensinaldosterone system, the complex entity of diabetes-related heart disease and the (emerging) evidence for specific inhibition of the renin-angiotensin-aldosterone system in diabetes.
Keywords: renin-angiotensin system, diabetes, cardiovascular disease
Current Vascular Pharmacology
Title: Diabetes, the Renin-Angiotensin System and Heart Disease
Volume: 1 Issue: 2
Author(s): Hoong Sern Lim and Gregory Y.H. Lip
Affiliation:
Keywords: renin-angiotensin system, diabetes, cardiovascular disease
Abstract: Despite recent advances, cardiovascular disease continues to be the leading cause of death among patients with diabetes. Diabetes-related heart disease makes up the majority of the cardiovascular morbidity and mortality and this clinical entity results from synergistic interaction amongst various overlapping mechanisms. Diabetes-related heart disease is characterised by a propensity to develop premature, diffuse atherosclerotic disease, structural and functional abnormalities of the microvasculature, autonomic dysfunction and intrinsic myocardial dysfunction (the so-called diabetic ‘cardiomyopathy’), all of which are exacerbated by hypertension and diabetic nephropathy. The renin-angiotensinaldosterone system possesses various autocrine and paracrine effects which drive most of the pathophysiological mechanisms in diabetes-related heart disease. This review aims to describe the expanding role of the renin-angiotensinaldosterone system, the complex entity of diabetes-related heart disease and the (emerging) evidence for specific inhibition of the renin-angiotensin-aldosterone system in diabetes.
Export Options
About this article
Cite this article as:
Lim Sern Hoong and Lip Y.H. Gregory, Diabetes, the Renin-Angiotensin System and Heart Disease, Current Vascular Pharmacology 2003; 1 (2) . https://dx.doi.org/10.2174/1570161033476682
DOI https://dx.doi.org/10.2174/1570161033476682 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regulatory Approaches to Nonclinical Reproductive Toxicity Testing of Anti-Cancer Drugs
Anti-Cancer Agents in Medicinal Chemistry A Review of Patents Relating to Therapeutic Angiogenesis Using Endothelial Progenitors and Other Vasculogenesis-Related Cell Types
Recent Patents on Regenerative Medicine Updated Electrocardiographic Classification of Acute Coronary Syndromes
Current Cardiology Reviews Impacts of Nanoparticles on Cardiovascular Diseases: Modulating Metabolism and Function of Endothelial Cells
Current Drug Metabolism PET Imaging of Beta-Adrenoceptors in Human Brain: A Realistic Goal or a Mirage?
Current Pharmaceutical Design Targeting the Arrhythmogenic Substrate in Atrial Fibrillation: Focus on Structural Remodeling
Current Drug Targets Patent Selections
Recent Patents on Cardiovascular Drug Discovery Pharmacological Therapy of Pericardial Diseases
Current Pharmaceutical Design Tissue Engineering Techniques in Cardiac Repair and Disease Modelling
Current Pharmaceutical Design Apoptosis in Anthracycline Cardiomyopathy
Current Pediatric Reviews Prognostic Role of miRNAs in Coronary Artery Disease
Current Topics in Medicinal Chemistry Parvovirus B19 (B19V) Infection and Pregnancy
Current Pediatric Reviews Meloxicam Prevents Load-Induced Cardiac Hypertrophy in Mice
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Polypharmacy- Purpose, Benefits and Limitations
Current Medicinal Chemistry Cardiac Biomarkers in Stroke, Alzheimer’s Disease, and Other Dementia. Are They of Use? A Brief Overview of Data from Recent Investigations
CNS & Neurological Disorders - Drug Targets Pleiotropic Effects of Simvastatin on Some Calcium Regulatory and Myofibrillar Proteins in Ischemic/Reperfused Heart: Causality of Statins Cardioprotection?
Current Pharmaceutical Design Actions of Rho-Kinase Inhibitors in Cardiovascular Diseases
Current Enzyme Inhibition Cruzipain, the Major Cysteine Protease of Trypanosoma cruzi: A Sulfated Glycoprotein Antigen as Relevant Candidate for Vaccine Development and Drug Target. A Review
Current Medicinal Chemistry Current Drug Nano-targeting Strategies for Improvement in the Diagnosis and Treatment of Prevalent Pathologies such as Cardiovascular and Renal Diseases
Current Drug Targets Statins and Cardiovascular Diseases: From Cholesterol Lowering to Pleiotropy
Current Pharmaceutical Design